Morgan Stanley participates in MBO of Chinese drug company

The management buyout, which has been accepted by shareholders owning 96% of the company, values Sihuan Pharmaceutical at $318 million – although only $74.4 million of new capital is needed.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition